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We report the presence of a new fatty acyl coenzyme A (acyl-CoA) elongation system in Cryptosporidium and
the functional characterization of the key enzyme, a single long-chain fatty acid elongase (LCE), in this
parasite. This enzyme contains conserved motifs and predicted transmembrane domains characteristic to the
elongase family and is placed within the ELO6 family specific for saturated substrates. CpLCE1 gene tran-
scripts are present at all life cycle stages, but the levels are highest in free sporozoites and in stages at 36 h
and 60 h postinfection that typically contain free merozoites. Immunostaining revealed localization to the outer
surface of sporozoites and to the parasitophorous vacuolar membrane. Recombinant CpLCE1 displayed
allosteric kinetics towards malonyl-CoA and palmitoyl-CoA and Michaelis-Menten kinetics towards NADPH.
Myristoyl-CoA (C14:0) and palmitoyl-CoA (C16:0) display the highest activity when used as substrates, and only
one round of elongation occurs. CpLCE1 is fairly resistant to cerulenin, an inhibitor for both type I and II fatty
acid synthases (i.e., maximum inhibitions of 20.5% and 32.7% were observed when C16:0 and C14:0 were used
as substrates, respectively). These observations ultimately validate the function of CpLCE1.
As one of the vital compounds for all organisms, fatty acids
of 14 to 18 carbons in length comprise the bulk of cellular fatty
acids that serve structural and biological functions, and they
are usually the major products of de novo synthesis in most
cells. These long-chain fatty acids play important roles in many
biological functions such as energy metabolism and membrane
structure. There are several metabolic pathways that produce
long-chain fatty acids, most notably the type I and type II fatty
acid synthases (FASs). The type I enzymes of mammals and
fungi are typically cytosolic and composed of multiple enzymes
arranged into domains of one or two large polypeptides (31).
In contrast, the enzymes of the type II FASs are all located on
separate domains and are found in prokaryotes or in eukary-
otic organelles of prokaryotic origin (33).
Relatively common among eukaryotic organisms are the
fatty acid elongase-based systems. These elongase-based sys-
tems directly elongate a fatty acyl chain esterfied with CoA
(fatty acyl-CoA), which is in contrast to the type I and type II
FAS systems, which elongate a fatty acyl chain attached to an
acyl carrier protein. The elongase system is comprised of at
least four enzymes that are responsible for adding two carbon
units to the fatty acyl carboxyl end. The chemistry of this
pathway is similar to that used by type I and type II FASs. Fatty
acyl elongation begins with the condensation of malonyl-CoA
with a fatty acyl-CoA catalyzed by the condensing enzyme LCE
(-ketoacyl-CoA synthase) (Fig. 1, step 1). The resulting -ke-
toacyl-CoA is then two carbons longer and is subsequently
reduced to -hydroxyacyl-CoA in an NAD(P)H-dependent re-
action by -ketoacyl-CoA reductase (Fig. 1, step 2). Dehydra-
tion occurs through the action of -hydroxyacyl-CoA dehy-
dratase to yield enoyl-CoA (Fig. 1, step 3), which is further
reduced by enoyl-CoA reductase in an NAD(P)H-dependent
manner (Fig. 1, step 4) to yield the elongated fatty acyl-CoA.
Whether or not the elongated product is released for use
elsewhere in the cell or is retained to undergo another round
of elongation depends largely on the specific needs of the
organism.
Although purification and biochemical characterization of
these four enzymes are difficult due to their membrane-bound
nature, it appears that the condensing enzyme is the rate-
limiting enzyme of the elongase system, and it is commonly
referred to as “elongase” (4, 8, 24). Thus, it is responsible for
the fatty acid substrate specificity regarding chain length and
pattern of double bonds, whereas the other three components
of the elongase system display little or no particular substrate
specificity (8). Comparative protein sequence analysis has clas-
sified the condensing enzymes into two distinct groups: the
KCS/fatty acid elongation group, present mainly in plants, and
the elongase (ELO) group, present in protozoa, mammals, and
fungi (16). It is not uncommon for a cell or organism to contain
multiple condensing enzymes that share the same reductase-
dehydratase-reductase enzymes. Furthermore, each system
within a cell or organism may exhibit a broad range of sub-
strate specificities (sometimes overlapping) for fatty acid chain
length as well as saturated or unsaturated fatty acids (16). For
example, Saccharomyces cerevisiae contains three elongases
termed ELO1, ELO2, and ELO3, in which ELO1 has a pref-
erence for elongating C12 to C16 fatty acids, whereas ELO2 and
ELO3 elongate C16 saturated and monounsaturated fatty acids
to C24 and C26, respectively (27). This study aims to charac-
terize the sole long-chain elongase from Cryptosporidium par-
vum (CpLCE1) and is the first such study among the apicom-
plexan parasitic protozoa.
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MATERIALS AND METHODS
Identification of CpLCE1 and phylogenetic reconstructions. The CpLCE1
gene was originally identified from a C. parvum genome contig by homology
searches and was then cloned and sequenced to confirm its identity (GenBank
accession No. AAO34582). It was later annotated in the genome sequencing
projects as a “7 pass integral membrane protein with FLHWFHH motif shared
with fatty-acyl elongase” for C. parvum (XP_627348) and as “fatty-acyl elongase”
for Cryptosporidium hominis (XP_666343).
To determine the evolutionary relationship of CpLCE1 to elongases from
other organisms, we performed maximum-likelihood (ML)-based phylogenetic
analyses. The CpLCE1 amino acid sequence was used as a query to search
protein databases, including all nonredundant GenBank CDS translations, Ref-
Seq Proteins, PDB, SwissProt, PIR, and PRF at the National Center for Bio-
technology Information (NCBI), using the PSI-BLAST program (http://www
.ncbi.nlm.nih.gov/BLAST) (2). Elongase sequences from other apicomplexans
were also obtained from http://PlasmoDB.org (Plasmodium) and http://ToxoDB
.org (Toxoplasma gondii). Four iterative BLAST searches were performed, and
only sequences with E values of better than 1  104 were selected for phyloge-
netic analysis.
Multiple-sequence alignments were performed on 75 sequences using the
ClustalW algorithm housed in the MacVector v9.5.2 program (MacVector, Inc.),
and apparent mistakes in alignment were corrected upon visual inspection. A
data set containing 91 unambiguously aligned amino acid positions was used in
subsequent analysis. The MrBayes v3.1.2 program (http://mrbayes.csit.fsu.edu/)
was used to reconstruct trees using a Bayesian inference method (12). The
program was allowed to “jump” among all available amino acid substitution
models and to consider among-site rate heterogeneity using a fraction of invari-
ance (Inv) plus a four-rate -distribution model during Markov chain Monte
Carlo analysis. A total of 5  106 generations of searches were performed with
two independent runs, each containing four chains simultaneously running. The
current trees were saved every 1,000 generations. Posterior probability (PP)
values at tree nodes were obtained by calculating consensus trees from the last
3,000 Bayesian inference trees that were obtained after the runs converged. In
addition, ML analysis was also performed using the PROML program included
in the PHYLIP package (http://evolution.gs.washington.edu/phylip.html). The
Jones-Taylor-Thornton model (14), with the consideration of Inv and four-
rate  that were estimated using the TREE-PUZZLE v.5.2 program (http:
//www.tree-puzzle.de).
Transcript analysis for CpLCE1 at various developmental stages. Freshly
isolated C. parvum oocysts (Iowa strain) purified by Percoll gradient centrifuga-
tion and stored in water at 4°C (3) were used to analyze the relative transcript
levels for the CpLCE1 gene. Oocysts were excysted in phosphate-buffered saline
(PBS) containing 0.1% trypsin and 0.5% taurodeoxycholic acid for 90 min at
37°C to release free sporozoites, which were further purified using a Percoll
gradient centrifugation method (29). Intracellular stages of C. parvum were
obtained by infecting human HCT-8 cells with oocysts for various times (6 to
72 h). Total RNA was isolated from oocysts, free sporozoites, and intracellular
stages using an RNeasy kit (QIAGEN) following the manufacturer’s recom-
mended protocol for animal cells. The only addition to RNA isolation using this
method was that oocysts were suspended in the recommended lysis buffer and
underwent 10 freeze-thaw cycles (liquid nitrogen and 37°C) to disrupt the oocyst
wall prior to RNA isolation.
A SYBR green-based real time quantitative reverse transcription-PCR (qRT-
PCR) method was used to determine the transcript levels of CpLCE1 at the
various developmental stages. The primer pair CpLCE1-F07 (5 TCA CTT TAT
CAG AAC CAA CGG TG 3) and CpLCE1-R07 (5GGC AGT TAC CCA TTC
AGC AAG 3) was used to amplify CpLCE1 transcripts. To amplify C. parvum
18S rRNA as a control for normalization, we used the previously reported
primers 995F (5 TAG AGA TTG GAG GTT GTT CCT 3) and 1206R (5 CTC
CAC CAA CTA AGA ACG GCC 3) (1). The relative level of CpLCE1 tran-
scripts was expressed relative to that of 18S rRNA, and values are reported based
on at least three replicates as previously described (5, 28).
Production of antibodies. A short peptide corresponding to a unique internal
sequence of CpLCE1 (76FGPKIMEKRKPFKLEKPLKYW) (Fig. 2) was synthe-
sized by the Peptide Core Facility at the Department of Veterinary Pathobiology,
Texas A&M University. This short peptide is unique to CpLCE1 and is reason-
ably antigenic as determined by various antigenicity indexes using the MacVector
v9.5.2 program (MacVector, Inc.). Initially, sera from six pathogen-free rats were
collected prior to the immunization protocol, of which preimmune sera from two
of the six showed no reactivity to dot blot tests using parasite protein extracts.
The synthetic peptide was freshly cross-linked to keyhole limpet hemocyanin
prior to each immunization. Polyclonal antibodies to CpLCE1 were raised in two
pathogen-free rats that were initially immunized with 200 mg of antigen emul-
sified in an equal volume of Freund complete adjuvant. Booster immunizations
(100 mg) were performed at 30 and 60 days, respectively, after the primary
immunization. Rat sera were then collected after the immunization protocol, and
specificity of the rat polyclonal antibodies was evaluated by dot and Western blot
analyses with protein extracts of parasites and host cells.
Immunofluorescence microscopy. Sporozoites and intracellular developmental
stages for immunolocalization analysis were obtained as described above. Intra-
cellular parasites were obtained by infecting human HCT-8 cells grown on glass
coverslips treated with poly-L-lysine for 12, 36, or 60 h. Samples were fixed with
10% formalin, rinsed with PBS, and extracted with cold methanol (20°C). Free
sporozoites were applied directly to poly-L-lysine-treated coverslips, air dried,
and then extracted. Cells were then blocked with 0.5% bovine serum albumin
(BSA)–PBS for 10 min before incubation with primary antibodies for 1 h in 0.5%
BSA–PBS. Free sporozoites were then labeled with anti-rat immunoglobulin
(IgG) secondary antibodies conjugated with fluorescein isothiocyanate (FITC)
for 1 h in 0.5% BSA–TBS. Intracellular developmental stages were all exposed
to a 1-h incubation in 0.5% BSA–PBS with anti-rat IgG–tetramethyl rhodamine
isocyanate (TRITC) to visualize CpLCE1 localization. Colocalization of
CpLCE1 with C. parvum fatty acyl-CoA binding protein (CpACBP1) and with
total membrane proteins (TMPs) was similarly performed. The anti-TMP anti-
bodies and FITC-conjugated secondary antibodies were incubated simulta-
neously with anti-CpLCE1 and corresponding secondary antibodies, respectively;
whereas the CpACBP1 antibodies were directly labeled with Alexa Fluor 488
using the appropriate fluorophore labeling kit (Invitrogen). Colocalization of
CpLCE1 with TMP or CpACBP1 was selected because the TMP antibodies have
been shown to label the parasitophorous vacuolar membrane (PVM) and feeder
organelle (7) and CpACBP1 localizes to the surface of merozoites as well as
colocalizes with TMPs (35). All samples were mounted with a SlowFade Gold
antifade reagent containing 4,6-diamidino-2-phenylindole (DAPI) for DNA
counterstaining (Invitrogen) and examined with an Olympus BX51 epifluores-
cence microscope equipped with differential interference contrast and TRITC/
FITC/DAPI filters.
Cloning and expression of CpLCE1. The 972-bp CpLCE1 gene was amplified
from C. parvum (Iowa strain) genomic DNA using the high-fidelity Pfu Ultra
DNA polymerase (Stratagene) with the primer sets CpLCE1-Fwd (5 gcg aat tcA
TGT TCA TAG AAA ATA ATA ATA AT 3) and CpLCE1-Rev (5 gct cta gaA
TCG CGC TTA GTT GGT TTT T 3) (lowercase represents artificial EcoRI
and XbaI linkers, respectively). The amplified product was directly ligated into
FIG. 1. The fatty acid elongation system. The diagram displays the
four enzymes and fatty acyl-CoA intermediates involved in the two-
carbon elongation of fatty acyl-CoAs. The first step is a condensation
reaction catalyzed by the “elongase” enzyme (CpLCE1). This is the
enzyme that determines chain length and degree of unsaturation of the
substrate, and it is the rate-limiting step of the system. The product of
the condensation reaction then undergoes reduction by a -ketoacyl-
CoA reductase (step 2), dehydration by -hydroxyacyl-CoA dehy-
dratase (step 3), and a final reduction by enoyl-CoA reductase (step 4).
Whether or not the elongated product is utilized elsewhere in the cell
or organism or undergoes an additional round(s) of elongation de-
pends largely on the needs of the specific cell/organism at that time.
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FIG. 2. Amino acid sequence comparison of CpLCE1 and representative eukaryotic elongase condensing enzymes. The cDNA-derived amino
acid sequence of CpLCE1 (accession no. AAO34582) is aligned with the deduced sequences of Toxoplasma gondii (20.m00392), Plasmodium
falciparum (XP_001351023), Trypanosoma cruzi (XP_813971), Leishmania major (CAJ03003), Homo sapiens (NP_076995), Mus musculus
(NP_569717), and Gallus gallus (NP_001026710). Amino acids with at least 50% conservation between CpLCE1 and other sequences are shaded.
The four highly conserved domains characteristic of the elongase family of enzymes are indicated below the sequence, and the six predicted
transmembrane domains are clearly outlined (labeled I to VI). Asterisks indicate the epitope used for antibody production.
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the pcDNA3.1/HisC mammalian expression vector (Invitrogen) and transformed
into Escherichia coli TOP10 cells (Invitrogen).
Plasmid DNA containing the correct insert (pcDNA3.1/HisC-CpLCE1) and
confirmed by sequencing was transfected into human embryonic kidney (HEK)-
293T cells. HEK-293T cells were plated in 100-mm tissue culture plates and
grown at 37°C in an atmosphere of 5% CO2 in Dulbecco’s modified Eagle
medium (high glucose) supplemented with 10% fetal bovine serum. At 90%
confluence the pcDNA3.1/HisC-CpLCE1 plasmid or the empty plasmid
pcDNA3.1/HisC (10 g) was transfected into cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. After transfection, cells
were grown for 48 h at 37°C in Dulbecco’s modified Eagle medium plus 10% fetal
bovine serum.
Confirmation of transfection and protein expression. At 48 hours after trans-
fection of HEK-293T cells, total RNA was isolated from CpLCE1- and
pcDNA3.1/HisC-transfected cultures and nontransfected cultures (as a negative
control) using an RNeasy minikit (QIAGEN) following the manufacturer’s pro-
tocol. The vector-specific T7-Fwd and BGH-Rev primers were used in conjunc-
tion with the one-step RT-PCR kit (QIAGEN) to confirm positive transfection.
Transfections were also performed in a 24-well format to assess protein ex-
pression using immunofluorescence microscopy. Cells were first seeded onto
glass coverslips treated with poly-L-lysine and transfected with CpLCE1 or
pcDNA3.1/HisC using the method described above while following the recom-
mended protocol for Lipofectamine 2000 transfection in the 24-well format.
After incubation for 48 h, cells were fixed with 10% formalin, rinsed with PBS,
extracted with 20°C methanol for 5 min, and blocked in 0.5% BSA–PBS for 10
min. Cells were then labeled with anti-CpLCE1 primary antibodies for 1 h in
0.5% BSA–PBS, followed by incubation with secondary antibodies conjugated
with TRITC for 1 h in 0.5% BSA–PBS. The samples were washed after each
incubation step three times with PBS for 5 min each. All samples were mounted
using DAPI and examined using an Olympus BX51 epifluorescence microscope
equipped with differential interference contrast and TRITC/DAPI filters. Cul-
tures that were not transfected or that were transfected with pcDNA3.1/HisC
were used as negative controls.
Preparation of total membrane transfected cells. TMP fractions were pre-
pared in a method similar to that for preparing microsomal protein (18). At 48
hours posttransfection, cells were washed with PBS and scraped into 5 ml of
ice-cold 250 mM sucrose, 20 mM HEPES (pH 7.5) containing a mammalian
protease inhibitor cocktail (Sigma). After centrifugation at 1,000  g for 7 min
at 4°C, the cell pellet was resuspended in 3 ml of ice-cold sucrose-HEPES with
protease inhibitors. The sample was then Dounce homogenized and centrifuged
at 1,000  g at 4°C to remove large cellular debris. The supernatant was then
centrifuged at 100,000 g for 1 h at 4°C. The supernatant was discarded, and the
resulting pellet was resuspended in 500 l of 100 mM Tris-HCl, 0.1% Triton
X-100 (pH 7.4). Protein concentration was determined by a Bradford colorimet-
ric method using BSA as a standard. Aliquots were snap frozen in liquid nitrogen
and stored at80°C. Western blot analysis using the rat anti-CpLCE1 antibodies
and monoclonal rabbit anti-rat IgG antibodies was also performed to test for the
presence of CpLCE1 in the prepared membrane fractions of transfected cells.
Fatty acyl-CoA elongation assay. Initial activity of the elongation of fatty
acyl-CoA by CpLCE1 was determined using variations of a mixture of previously
described methods (18, 22, 30, 32). To optimize reaction conditions, a 100-l
reaction mixture containing 50 mM potassium phosphate (pH 6.5), 5 M rote-
none, 20 M fatty acid-free BSA, 1 mM MgCl2, 0.5 mM NADH, 0.5 mM
NADPH, 60 M palmitoyl-CoA, and 200 M [2-14C]malonyl-CoA was heated at
37°C for 2 min. The reaction was started with the addition of 30 g of protein
from CpLCE1- or pcDNA3.1/HisC-transfected cells and allowed to proceed for
30 min at 37°C before the addition of 100 l of 5N KOH in 10% methanol. The
samples were then saponified at 65°C for 1 h and cooled to room temperature,
when 100 l each of 5 N HCl and ethanol were added. Radiolabeled incorpo-
rated fatty acids were then extracted from the mixture using 1 ml of hexane
followed by vigorous mixing and centrifugation at 10,000  g for 2 min. The
upper organic phase was removed, while the lower aqueous phase was washed
twice more with 1 ml of hexane. The hexane extracts were pooled and dried
under vacuum, and then 5 ml of scintillation fluid was added and the radioactivity
was counted in a Beckman Coulter LS 6000SE counter. Activity was determined
by subtracting the values obtained for the pcDNA3.1/HisC-transfected samples
from the values obtained for the CpLCE1-transfected samples. Reaction mix-
tures containing no membrane protein were also used as controls to determine
additional background levels.
Dependence on NADH or NADPH was determined using the same assay, and
the optimum pH for this enzyme was determined using the reaction described
above with inclusion of 50 mM potassium phosphate buffer at pH 5.0, 5.5, 6.0,
and 6.5 and 50 mM Tris buffer at pH 7.0, 7.5, 8.0, and 8.5. The kinetics for
CpLCE1 were similarly assayed using various amounts of palmitoyl-CoA (0.98 to
250 M), malonyl-CoA (0.98 to 500 M), and NADPH (3.9 M to 1 mM).
Substrate preference. Once optimal reaction parameters were known, the
substrate preference for CpLCE1 was determined. The fatty acyl-CoA elonga-
tion assay used was similar to that described above except it lacked NADH
(included 500 M NADPH) and included 125 M of various saturated (C2:0 to
C24:0) and unsaturated (C18:1, C18:3, C20:4, and C22:6) fatty acyl-CoAs and 250
M [2-14C]malonyl-CoA. Reaction mixtures included protein fractions from
either CpLCE1- or pcDNA3.1/HisC-transfected samples. Activity was deter-
mined by subtracting values obtained for the pcDNA3.1/HisC-transfected sam-
ples from the values obtained for the CpLCE1-transfected samples. Additionally,
substrate preference data were used to test the inhibitory effect of cerulenin, a
known inhibitor of both type I and II -ketoacyl-CoA synthase, on CpLCE1
using the same reaction conditions as described above and including 0.2 to 200
M cerulenin.
TLC analysis of elongated fatty acids. The fatty acid elongation reaction was
assayed as described above using 30 g protein from either CpLCE1- or
pcDNA3.1/HisC-transfected cells, 250 M nonradiolabeled malonyl-CoA, and
125 M of either myristoyl-CoA or palmitoyl-CoA (C14:0-CoA and C16:0-CoA,
respectively). Reactions were terminated and fatty acids were extracted as de-
scribed above. Hexane fractions containing the elongated fatty acids were dried
by evaporation under nitrogen before the addition of 3 ml methanol-toluene-
sulfuric acid (88:10:2, vol/vol) to convert the extracted fatty acids into their fatty
acid methyl ester (FAME) derivatives (11, 30). The suspension was incubated for
1 h at 80°C and allowed to cool to room temperature, and FAMEs were extracted
two times with 2 ml hexane. The hexane fractions were once again allowed to
evaporate to dryness under nitrogen and were resuspended in 40 l hexane for
thin-layer chromatography (TLC) analysis. Reverse-phase LKC18 silica gel 60-Å
TLC plates (Whatman, Inc.) were washed with chloroform-methanol (1:1), fol-
lowed by incubation at 110°C for 1 h and cooling to room temperature before
samples were spotted. The elongated products were separated using methanol-
chloroform-water (15:5:1) with authentic FAME standards (Supelco) (25).
HPLC analysis of elongated fatty acids. The elongation assay and FAME
preparation used for high-pressure liquid chromatography (HPLC) analysis were
replicas of that used for TLC analysis except that the FAMEs were suspended in
200 l 65% acetonitrile in water instead of 40 l hexane. FAME derivatives of
the elongation products were separated by reverse-phase HPLC using a Shi-
madzu Prominence HPLC and a Zorbak SB-C18 semipreparative column (5 m,
9.4 by 250 mm; Agilent Technologies). Injection volumes were 100 l, and
elution was performed using a binary gradient of 95% acetonitrile–5% water at
a flow rate of 1.0 ml/min. The absorbance at 205 nm (A205) was monitored using
an SPD-M20A diode array detector, and the retention times of the eluted
products were compared to those of known FAME standards (Supelco) origi-
nally suspended in 65% acetonitrile.
RESULTS
Sequence comparison of elongases related to CpLCE1. In
contrast to the case for many other eukaryotic organisms,
CpLCE1 is the only elongase gene homologue that can be
identified from the C. parvum genome. This intronless gene
encodes 324 amino acids that share several characteristics with
related elongase homologues. Figure 2 displays the CpLCE1
amino acid sequence aligned with those of selected mamma-
lian and protozoan elongases. The Toxoplasma gondii elongase
sequence had the highest similarity with CpLCE1 (45% iden-
tical), while the six others were between 31% and 38% iden-
tical. The alignment shows that all the sequences share the
characteristic FLHxxHH motif that is conserved among elon-
gases and even fatty acid desaturases. Additionally, the KxxE
xxDT, NxxxHxxMYxYY, and TxxQxxQ motifs are present,
which are also characteristic among elongases and appear to be
highly conserved especially among the polyunsaturated fatty
acid elongases (19). Structural analysis of CpLCE1 aligned
with these related elongases revealed several hydrophobic do-
mains. Analysis with the TMAP algorithm (26) predicts six
transmembrane domains which are clearly indicated. This is
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typical of elongases and confirms the suggestion that CpLCE1
is anchored to a membrane.
Phylogenetic relationships among apicomplexan and other
eukaryotic elongases. Thousands of elongase homologues were
identified from BLAST searching the GenBank protein data-
bases. Because our goal was to obtain information about the
evolution of apicomplexan elongases rather than to take a
global approach to analyze the elongase protein family, we
constructed phylogenetic trees from a total of 75 taxa from a
variety of other organisms. Applying a Bayesian analysis to the
phylogeny resulted in distinct groups organized both by the
type of elongases and, to a minimal extent, by the taxonomy
(Fig. 3). Although the apicomplexan elongases do not form a
monophyletic clade, all of the protozoans, including both
apicomplexans and the kinetoplastids (Trypanosoma and
Leishmania), remain clustered together. Similar to the case
for previous phylogenetic reconstructions (17), the putative
kinetoplastid elongases group together in a clade exclusive to
this group of parasites. With respect to putative saturated fatty
acid elongases among the apicomplexans, they form two
clades, both of which appear to be closely related to the ELO6
family of saturated fatty acid elongases.
CpLCE1 is differentially expressed and is localized to the
PVM. To determine the CpLCE1 expression pattern in the
complex parasite life cycle, real-time qRT-PCR and immuno-
fluorescence detection were performed. Real-time qRT-PCR
analysis indicated that the CpLCE1 gene is differentially ex-
pressed in the C. parvum life cycle stages (Fig. 4A). Relative
transcript levels also increased at 36 h postinfection (p.i.), and
to a minor extent at 60 h p.i., but were detectable at all time
points. The free sporozoites (a motile invasive stage of the
parasite) exhibited a much higher level of CpLCE1 transcripts
than all other life cycle stages. The presence of CpLCE1 in
protein extracts from sporozoites was clearly displayed by
Western blot analysis using polyclonal rat anti-CpLCE1 anti-
bodies (Fig. 4B).
FIG. 3. ML tree derived from 75 elongase sequences (91 amino acid positions) using a Bayesian analysis of phylogeny. PP values at major nodes
are indicated as percent values. Solid diamonds, 100%; solid circles, 90 to 99%. These PP values were derived from 3,000 trees obtained after the
ML values converged. In the large tree, only the elongase family of proteins are shown as references. The large tree with GenBank gene
identification (GI) numbers and species names for all taxa is provided in the supplemental material or can be requested from the corresponding
author. Additional ML analysis using the PROML program yielded essentially the same topology shown here.
FIG. 4. Expression analysis of the CpLCE1 gene in various C. par-
vum life cycle stages. (A) Relative transcript levels were determined
using real-time qRT-PCR. The level of transcripts is normalized using
the level of C. parvum 18S rRNA as a control. For all samples, bars
represent the standard errors of the means from triplicate reactions.
(B) Western blot analysis using polyclonal rat anti-CpLCE1 antibodies
of protein extracted from freshly excysted sporozoites.
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Immunofluorescence microscopy indicates that CpCLE1 is
present in free sporozoites and localizes to the sporozoite
membrane (Fig. 5A). Furthermore, CpLCE1 localizes to the
PVM during intracellular development (Fig. 5B and C). This
was determined by two separate colocalization studies. Dual-
labeling experiments using a rabbit polyclonal antibody mainly
against the PVM and the electron-dense feeder organelle co-
localized CpLCE1 and PVM proteins (Fig. 5B). It has previ-
ously been shown that CpACBP1 also colocalizes with the
PVM proteins (35). An additional dual-labeling experiment
using rabbit polyclonal antibodies against CpACBP1 colocal-
ized CpLCE1 and CpACBP1 proteins (Fig. 5C). Combined,
CpLCE1 localizes to the PVM but not the merozoites within
the meronts.
Cloning and expression of CpLCE1. Previous attempts in
our laboratory to express and purify recombinant CpLCE1 in
bacteria were unsuccessful, typically resulting in the formation
of inclusion bodies. However, this is consistent with the elongase
family of enzymes, as they tend to have a membrane-bound na-
ture. Therefore, we expressed CpLCE1 in mammalian HEK-
293T cells for characterization of this enzyme. HEK-293T cells
were used because they offer several advantages. It is widely
accepted that this cell line displays a very high level of trans-
fection efficiency. This, in combination with using the
pcDNA3.1/HisC expression vector, allows for high-level non-
replicative transient expression. Additionally, these cells also
contain their own native elongase system. Thus, recombinant
CpLCE1 acts in conjunction with the native HEK-293T elon-
gase system in order to carry out the entire two-carbon fatty
acid elongation cycle. However, this can sometimes be a dis-
advantage due to recombinant and native elongase enzymes
competing for the same substrate. This often results in a rela-
tively high degree of background activity that must be taken
into consideration when interpreting data obtained from using
a heterologous assay system.
Successful transfection and protein expression using this
method were analyzed using RT-PCR, Western blotting, and
immunolabeling. Total RNA was isolated from cells trans-
fected with either CpLCE1 or pcDNA3.1/HisC (and nontrans-
fected cells as a negative control) at 48 h after transfection, and
vector-specific primers were used during RT-PCR to confirm
positive transfection. Amplicons of the correct size corre-
sponding to pcDNA3.1/HisC- and CpLCE1-transfected cells
were observed (259 bp and 1,195 bp, respectively) (Fig. 6A).
Western blot analysis of the membrane fractions using rat
polyclonal antibodies against CpLCE1 clearly confirmed that
CpLCE1 is expressed and indicated that it is contained in the
purified membrane fractions (Fig. 6B). Immunofluorescence
microscopy indicated that this protein was expressed relative to
cells transfected with pcDNA3.1/HisC or nontransfected cells
(Fig. 6C). The fluorescent signal was largely increased for the
CpLCE1-transfected cells and could be observed using a rela-
tively low exposure time (280 ms). At the same exposure there
was no observed fluorescent signal from pcDNA3.1/HisC-
transfected or nontransfected cells. Only at an exposure time
of 9.8 s did a fluorescence signal begin to appear in these
samples (Fig. 6C, insets) indicating that the CpLCE1-trans-
fected cells were indeed expressing the desired protein.
Determination of enzyme activity. It is imperative that we
first clarify the elongation assay in order for the results to be
appropriately understood. The membrane preparations of
HEK-293T cells used in this study contain all four enzymes of
the elongase system. Thus, in samples that have been trans-
fected with CpLCE1, there are two sets of condensing enzymes
which are responsible for the incorporation of 14C from
[2-14C]malonyl-CoA. The products formed during the initial
condensation reaction (catalyzed by the native elongase and by
CpLCE1) then proceed through the subsequent three steps of
the elongation system (-ketoacyl-CoA reductase, -hydroxy-
acyl-CoA dehydratase, and enoyl-CoA reductase) to produce a
final two-carbon extended product (see Fig. 1 for reaction
details). Therefore, there is detectable background activity that
is present when using this heterologous system and must be
distinguished from activity produced by recombinant CpLCE1.
Total fatty acid elongation activity was measured in isolated
membrane fractions of HEK-293T cells transfected with
CpLCE1 and compared with that in HEK-293T cells trans-
fected with the empty vector alone (pcDNA3.1/HisC). Super-
natant fractions resulting from the membrane purification pro-
cess were also used as controls. Palmitoyl-CoA (C16:0-CoA)
was initially chosen as the fatty acid substrate for the elonga-
tion assay, which measured the incorporation of 14C from
[2-14C]malonyl-CoA into elongated fatty acid products. Total
elongation activity was increased in the membrane fractions
from CpLCE1-transfected cells compared to cells transfected
with the empty vector (Fig. 7A). The activities detected in the
supernatant fractions of CpLCE1- and pcDNA3.1/HisC-trans-
fected cells were not significantly different from each other but
FIG. 5. Immunolocalization of CpLCE1 in free sporozoites and in
intracellular life stages. (A) Indirect immunolabeling of freshly ex-
cysted sporozoites using rat polyclonal antibodies against CpLCE1
along with secondary antibodies conjugated with TRITC. DAPI, used
for counterstaining nuclei, is merged with the image on the right.
(B) Colocalization of CpLCE1 (TRITC) with parasite TMPs (FITC)
of parasites grown for 36 h. The antibodies against parasite TMPs
mainly label the PVM and the electron-dense feeder organelle.
(C) Dual labeling of intracellular parasites grown for 60 h indicating
that CpLCE1 colocalizes with CpACBP1, which has previously been
shown to colocalize with parasite TMPs, most likely at the PVM.
Phase, phase-contrast microscopy; DIC, differential interference con-
trast microscopy. Bars, 5 m.
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were significantly higher than the activity detected in the mem-
brane fractions (Fig. 7A). The activity in the supernatant frac-
tions is expected due to the soluble enzymes that use malonyl-
CoA as a cosubstrate, such as the soluble FAS enzymes. Thus,
in agreement with Western blot and immunofluorescent anal-
ysis (Fig. 6B and C, respectively) the CpLCE1 activity is con-
tained in the membrane fractions of cells transfected with
CpLCE1.
To further confirm that the observed activity was indeed that
of the elongase complex, we separately incubated membrane
fractions with or without NAD(P)H (Fig. 7B). When NADH
was used as a cosubstrate, activity was detected in both the
CpLCE1- and pcDNA3.1/HisC-transfected samples; however,
these activities were not significantly different from each other,
confirming that the subsequent reduction reactions of the elon-
gation system do not utilize NADH as a cosubstrate. The
activity observed here is due to a partial contribution of other
membrane enzymes that make use of NADH. When NADPH
was used as the sole cosubstrate, the membrane fractions from
the CpLCE1-transfected cells displayed a significantly greater
elongation activity than those from the cells transfected with
the vector alone. Combined, these data confirm that NADPH
is the required cosubstrate for the elongation system reduction
reactions and that CpLCE1 is capable of carrying out the initial
reaction of the elongase system.
Optimization of CpLCE1 assay and enzyme kinetics. Be-
cause palmitoyl-CoA could serve as a substrate for CpLCE1, it
was used to optimize the conditions of the elongation reaction
prior to testing additional fatty acid substrates to determine
substrate specificity. The highest rate of [14C]malonyl-CoA
incorporation into elongated fatty acid products was observed
when the concentration of palmitoyl-CoA was 125 M (Fig.
8A). Additionally, enzyme kinetics analysis revealed that
CpLCE1 displayed typical Michaelis-Menten kinetics towards
palmitoyl-CoA (h	 1, Km	 73.30 M, and Vmax 	 67.64 U [1
U 	 1 pmol/min/mg of TMP]) (Fig. 8A). However, further
analysis indicated that the CpLCE1 kinetics actually fit better
to a sigmoidal curve (r2 	 0.9707 versus 0.9577), indicating the
presence of positive cooperativity (Fig. 8A). Under the con-
sideration of cooperativity, the values for K50 (equivalent to
Km) and Vmax were determined to be 43.76 M and 52.74 U,
respectively. Analysis of the kinetics of CpLCE1 towards
malonyl-CoA revealed similarities to that observed towards
palmitoyl-CoA. While the optimal concentration of malonyl-
FIG. 6. Confirmation of successful transfection and expression of
CpLCE1. (A) At 48 h posttransfection, total RNA was isolated from
cells transfected with CpLCE1 or the empty vector and from nontrans-
fected cells. RT-PCR analysis viewed on a 2% agarose gel indicated
that both the vector and the vector containing the CpLCE1 construct
were effectively transfected. (B) Western blot analysis of the purified
membrane fractions from cells transfected with CpLCE1 or
pcDNA3.1/HisC. Eighty micrograms of protein from each fraction was
separated on a 10% sodium dodecyl sulfate-polyacrylamide gel, trans-
ferred to nitrocellulose, and labeled with rat polyclonal antibodies
against CpLCE1. Further incubation with rabbit anti-rat antibodies
conjugated to alkaline phosphatase followed by development with
5-bromo-4-chloro-3-indolylphosphate resulted in a single band corre-
sponding to CpLCE1. (C) Immunofluorescence detection of CpLCE1
protein expression. Nontransfected cells were used as a negative con-
trol. Clearly, the fluorescence intensity when labeling with rat anti-
CpLCE1 antibodies followed by rabbit anti-rat IgG conjugated to
TRITC was highest in cells transfected with CpLCE1. A 35-fold in-
crease in exposure time (280 ms versus 9.8 s) was required to detect
only minor fluorescence intensity in pcDNA3.1/HisC-transfected cells
(comparable to nontransfected cells; both are shown as insets).
FIG. 7. Elongase activity determination and NADPH dependence.
(A) The final pellet fraction after membrane purification of CpLCE1-
transfected cells displayed higher elongase activity than that from cells
transfected with the empty vector. Both NADH and NADPH were
used as cosubstrates. The high activity observed in the soluble fractions
likely results from soluble proteins utilizing malonyl-CoA and
NAD(P)H. (B) Total elongation activity as measured when including
various combinations of NAD(P)H. As expected, the most significant
difference among fractions containing CpLCE1 and control fractions
was observed when using NADPH as the sole cosubstrate. Values were
obtained by subtracting the activity detected using fractions from cells
transfected with the empty vector. Values are represented as pmol/
min/mg of TMP. In all samples, bars represent the standard errors of
the means from triplicate reactions.
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CoA was 250 M, CpLCE1 displayed a slightly better fit to a
sigmoidal curve (Fig. 8B) (r2	 0.9387). This is a slight negative
cooperativity with a K50 of 15.45 M and a Vmax of 50.97 U
compared to the general Michaelis-Menten kinetics (Fig. 8B)
(r2 	 0.9265). When using increasing concentrations of
NADPH, general Michaelis-Menten kinetics were observed
(Fig. 8C), with a Km of 61.53 M and a Vmax of 62.19 U, and
the optimum concentration of NADPH was 500 M. The
observed NADPH kinetics are in respect to the two reduction
reactions that occur as a result of activity initiated by CpLCE1,
the condensation reaction. Fatty acid elongation activity was
also determined to be highest at a pH optimum of 6.5
(Fig. 8D).
CpLCE1 displays the highest activity towards C14:0 and
C16:0. Using the optimal assay conditions found above, we
determined the substrate specificity of CpLCE1 using a wide
range of fatty acyl-CoAs. Figure 9 shows the total fatty acid
elongation activity in membrane fractions from CpLCE1-
transfected HEK-293T cells using even-carbon saturated fatty
acyl-CoAs from C2:0 to C24:0 and the unsaturated (or polyun-
saturated) fatty acyl-CoAs C18:1, C18:3, C20:4, and C22:6. Com-
pared to membrane fractions from pcDNA3.1/HisC-trans-
fected cells, the cells expressing recombinant CpLCE1
displayed significantly higher elongase activities when assayed
with the medium- to long-chain fatty acyl-CoAs C10:0 to C18:0
and the highest with C14:0 and C16:0. Relatively little to no
activity above background was detected when short- or very-
long-chain fatty acyl-CoAs were used as substrates. Interest-
ingly, arachidonic acid (C20:4) was the only unsaturated fatty
acid that displayed a rather significant activity above back-
ground. This was not expected and is considered to be an
artifact due to in vitro assay conditions.
Analysis of elongation products. The two fatty acyl-CoAs
shown to display the highest elongated activity when used as
substrates (myristoyl-CoA and palmitoyl-CoA) were used to
analyze the elongated products by both TLC and HPLC. Upon
completion of the reaction, the elongation fatty acid products
were methylated to their methyl ester derivatives for compar-
ison with FAME standards. When elongation products of
membrane fractions from CpLCE1-transfected cells were an-
alyzed using reverse-phase TLC, the major products were
palmitic acid (C16:0) and stearic acid (C18:0) when incubated
FIG. 8. Enzyme kinetics of the condensation reaction and kinetics and pH optimum for the overall elongation system. (A) Allosteric kinetics
assayed with various concentrations of palmitoyl-CoA indicates the presence of positive cooperativity in the condensation reaction (Hill coefficient
[h] 	 1.727). The optimum palmitoyl-CoA concentration was 125 M. (B) Allosteric kinetics assayed with various concentrations of malonyl-CoA
indicates the presence of negative cooperativity (h 	 0.703) with an optimum concentration of 250 M. (C) Enzyme kinetics assayed with various
concentrations of NADPH. As the two reduction steps of the elongation system require NADPH, the results show that when using palmitoyl-CoA
as a substrate and CpLCE1 as the condensing enzyme, the elongase system displays general Michaelis-Menten kinetics. (D) The optimum pH of
the condensing enzyme is 6.5. Values were obtained by subtracting the activity detected using fractions from cells transfected with the empty vector.
Values are represented as pmol/min/mg of TMPs. For all samples, bars represent the standard errors of the means from triplicate reactions.
FIG. 9. Substrate specificity of CpLCE1. Saturated fatty acyl-CoAs
from C2:0 to C24:0 and various unsaturated fatty acyl-CoAs were used
to determine the substrate preference of the condensing enzyme. Val-
ues were obtained by subtracting the activity detected using fractions
from cells transfected with the empty vector. Values are represented as
pmol/min/mg of TMPs. For all samples, bars represent the range of
values from two sets of triplicate reactions.
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with myristoyl-CoA (C14:0) or palmitoyl-CoA (C16:0), respec-
tively (Fig. 10A). As a background control, membrane frac-
tions from cells transfected with pcDNA3.1/HisC were also
analyzed using TLC. The major product of the control when
using palmitoyl-CoA as a substrate was stearic acid. However,
when incubated with myristoyl-CoA, there were two products
detected on TLC, palmitic acid and stearic acid, indicating that
membrane fractions not transfected with CpLCE1 were capa-
ble of additional rounds of elongation. In either case, the
production of a two-carbon elongated product by the CpLCE1-
transfected cells resulted in a significantly larger quantity than
that with the pcDNA3.1/HisC-transfected samples.
To ensure that only one round of elongation was occurring
in membrane fractions transfected with CpLCE1, the elonga-
tion products were also analyzed using HPLC. If additional
rounds of elongation were indeed occurring, then the higher-
sensitivity HPLC analysis would detect multiple products. Sim-
ilar to analysis of the elongation reaction with TLC, FAMEs
were derived from the elongated products for comparison to
methyl ester standards. Analysis by HPLC agreed with TLC
analysis, further indicating that only one round of elongation
occurs in the CpLCE1-transfected samples. When incubation
was with myristoyl-CoA as a substrate, palmitic acid was de-
tected (Fig. 10B), and when palmitoyl-CoA was used as a
substrate, the addition of two carbons resulting in stearic acid
was detected (Fig. 10C). In both instances, the substrate was
also detected, indicating that not all substrate was converted
into an elongated product.
Inhibition of elongation by cerulenin. Cerulenin is a com-
mon eukaryotic and bacterial -ketoacyl-[acyl carrier protein]
synthase inhibitor. Initially, we tested its inhibitory effects using
palmitoyl-CoA as the substrate, where cerulenin displayed a
maximum inhibition of 20.5% at a concentration of 200 M
(Fig. 11, solid line). Because differential inhibition of cerulenin
has been shown to occur depending on fatty acid chain length
(23), we also tested inhibition with myristoyl-CoA as a sub-
strate. However, similar to the case with palmitoyl-CoA as a
substrate, cerulenin displayed a maximum inhibition of 32.7%
at a concentration of 200 M (Fig. 11, dotted line). Thus,
CpLCE1 appears to be relatively insensitive to cerulenin up to
200 M when both myristoyl-CoA and palmitoyl-CoA are used
as substrates.
DISCUSSION
Among the apicomplexans, CpLCE1 is the first elongase to
be studied, and it is one of very few studied among the parasitic
protists. It is interesting that the C. parvum genome encodes
only one elongase, whereas both T. gondii and Plasmodium
falciparum contain three. However, differences in fatty acid
metabolism (and lipid metabolism in general) among these
organisms do exist. Among the apicomplexans that possess a
plastid and associated type II FAS, P. falciparum lacks a type I
FAS or polyketide synthase (PKS), but T. gondii and Eimeria
tenella both possess a type I FAS and PKS (40). Similarly, C.
FIG. 10. Fatty acid elongation product analysis using TLC and
HPLC. (A) The products of fatty acid elongation were converted to
their methyl ester derivatives for analysis using reverse-phase TLC.
Both myristoyl-CoA and palmitoyl-CoA (C14:0 and C16:0, respectively)
were used as substrates based on the substrate preference data.
(B) HPLC analysis of elongation products converted to methyl esters
is comparable to that using TLC. The data show that only one round
of elongation occurs regardless of the fatty acyl substrate used. Reten-
tion times of all samples were compared to those of authentic fatty acid
methyl standards. HPLC peaks were detected as A205.
FIG. 11. Inhibitory effect of cerulenin on the activity of CpLCE1.
The inhibition effects when using both myristoyl-CoA (C14:0) and
palmitoyl-CoA (C16:0) were assayed. Values were obtained by subtract-
ing the activity detected using fractions from cells transfected with the
empty vector. Values are represented as total [14C]malonyl-CoA in-
corporation (pmol) based on a total of 30 g membrane protein. For
all samples, bars represent the range of values from two sets of trip-
licate reactions.
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parvum contains only a type I FAS and PKS (10, 38, 39, 41).
Thus, it is not a surprise that C. parvum, with its very stream-
lined metabolism, contains only one elongase.
Generally, fatty acid elongases are divided into two groups:
(i) those involved or suspected to be involved in the elongation
of saturated and monounsaturated fatty acids and (ii) those
that are responsible for elongation of polyunsaturated fatty
acids (13). Those of the first group are typically of the ELO1,
-3, and -6 families, whereas the latter group consists of the
ELO2, -4, and -5 families. Molecular analyses of CpLCE1
indicated that it contains structural characteristics possessed by
the elongase family, including four highly conserved motifs and
several predicted transmembrane domains. Furthermore, phy-
logenetic reconstructions indicate that CpLCE1 is contained
within the ELO6 family. This family is suggested to be involved
in the elongation of C12:0 to C16:0 saturated fatty acid sub-
strates to C18:0 products and do not have the ability to elongate
beyond C18:0 (13). The majority of the kinetoplastid elongases
analyzed form a clade with the ELO6-like apicomplexan elon-
gases, suggesting that all of these originated from a common
ancestor. Additionally, CpLCE1 appears to be more distant
from unsaturated elongase families.
Real-time qRT-PCR indicated that CpLCE1 transcript lev-
els are expressed in all stages of the C. parvum life cycle but are
highest in the sporozoites, followed by stages at 36 h and 60 h
p.i. In addition to membrane localization in sporozoites, im-
munostaining has localized CpLCE1 primarily to the PVM,
similar to the case for both CpACBP1 and the C. parvum
oxysterol binding protein-related protein 1 (CpORP1) (35, 36).
Cryptosporidium parvum is an intracellular parasite, but it is
considered extracytoplasmic because of being covered by a
PVM on the host intestinal epithelial cells (6). Although asso-
ciation with the feeder organelle is still undetermined, it is
interesting that CpLCE1 localizes to the PVM along with
CpACBP1 and CpORP1, which could possibly be involved in
lipid uptake across the PVM (35, 36). Whether CpLCE1 acts in
conjunction with these two in either lipid uptake or formation
of the PVM is not understood at this time. Regardless, PVM
proteins may serve as prime chemotherapeutic and/or immu-
notherapeutic targets in this parasite, for which fully effective
treatment is currently unavailable.
The extreme hydrophobicity of elongase proteins has caused
many difficulties in the solubilization and purification of these
membrane-bound condensing enzymes and has greatly hin-
dered the biochemical characterization of their defined roles in
fatty acid elongation. Nearly all enzymatic studies of these
elongase enzymes have been carried out using membrane frac-
tions. Thus, we expressed CpLCE1 in mammalian HEK-293T
cells in order to characterize the biochemical features of this
enzyme.
Substrate preference revealed that CpLCE1 displays the
highest activity when myristoyl-CoA and palmitoyl-CoA (C14:0
and C16:0, respectively) are used as substrates. This is in agree-
ment with phylogenetic reconstructions that grouped CpLCE1
with the ELO6 family of elongases, which generally prefer
C12:0 to C16:0 as substrates. It is interesting that CpLCE1
showed little to no preference for all other saturated and
unsaturated substrates except for arachidonyl-CoA (C20:4). It
is unknown whether this is due to in vitro effects or whether
CpLCE1 would potentially have the ability to elongate C20:4 in
vivo. Although total lipid analysis studies of C. parvum are
lacking, one report suggests that C20:4 comprises only 0.7% of
the total neutral fatty acid content in C. parvum and 2.3% and
1.2% in the total phospholipid and phosphatidylcholine con-
tent, respectively (20), indicating that C20:4 is present in only
small amounts in C. parvum. However, the C22 product of
elongation was not detected. No other enzyme involved in C.
parvum fatty acid metabolism has displayed preference for an
unsaturated substrate, which leads us to believe that elongation
of arachidonyl-CoA is an assay artifact.
Analyses of the CpLCE1-catalyzed elongation products in-
dicate that only one round of elongation occurs, thus extending
the length of each substrate by only two carbons. The factors
that determine exactly how many rounds of elongation occur
are unknown and could rely on the needs of the individual cell
or organism at the time in which elongation occurs. Our sub-
strate preference data indicated that both myristoyl-CoA and
palmitoyl-CoA are capable of serving as substrates. However,
it is intriguing that the longest-chain product observed when
using C14:0 as a substrate was C16:0. It is not clear why the
elongated C16:0 does not serve as a substrate itself and undergo
another round of elongation. This could be an artifact due to
heterologous assay conditions; however, other elongase en-
zymes expressed and assayed using similar methods clearly
demonstrate as many as three rounds of elongation (21).
Cerulenin was shown to have a minimal effect on inhibition
of CpLCE1, with a maximal inhibition of 20.5% and 32.7%
when using the substrates C16:0-CoA and C14:0-CoA, respec-
tively. This is interesting due to the ability of cerulenin to
efficiently inhibit both type I and type II -ketoacyl-CoA syn-
thases, which was the case for the control fractions transfected
with pcDNA3.1/HisC. At low concentrations of cerulenin
(2.1 M), activity was inhibited by 80% and remained con-
stant over the tested concentrations (data not shown). The
observed activity of cerulenin on CpLCE1 could be due to two
factors: (i) the alkyl chain of cerulenin could be too long to
bind to the active site of the enzyme (15), or (ii) the active site
serving as the target of cerulenin could be somewhat inacces-
sible due to the extreme hydrophobicity of the enzyme (34).
Elongase enzymes of other types and different families from
various organisms have also shown differential inhibition by
cerulenin. For example, the plant-type elongases appear to be
fairly resistant (9, 25), whereas ELO2 and ELO3 but not ELO1
from Trypanosoma is susceptible (15). Further analyses on the
ELO6 family of enzymes as well as elongase enzymes purified
to homogeneity are needed in order to fully and accurately
determine the effects of cerulenin.
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